MeiraGTx (MGTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of three directors: Ellen Hukkelhoven, Nicole Seligman, and Debra Yu.
Proposal to ratify Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be transacted as properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Audit committee and external auditor matters
Ernst & Young LLP is proposed for ratification as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MeiraGTx
- Director elections, auditor ratification, and robust governance highlight this year's proxy.MGTX
Proxy filing30 Apr 2026 - AAV-AQP1/AAV-hAQP1 delivers durable, transformative benefit for persistent xerostomia.MGTX
KOL event16 Apr 2026 - Pivotal gene therapy programs and Riboswitch platform drive late-stage pipeline and market growth.MGTX
Corporate presentation16 Apr 2026 - Breakthrough designations, strategic deals, and improved financials drive pipeline and outlook.MGTX
Q4 202526 Mar 2026 - Late-stage gene therapy programs and strategic partnerships drive global filings and pipeline growth.MGTX
RBC Capital Markets Virtual Ophthalmology Conference26 Mar 2026 - Pivotal programs and riboswitch innovation accelerate cost-effective therapy development.MGTX
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Late-stage genetic medicine programs and the Riboswitch platform promise broad clinical impact.MGTX
Chardan's 8th Annual Genetic Medicines Conference20 Jan 2026 - Transformative gene therapies advance in rare blindness, xerostomia, and Parkinson's, with strong regulatory support.MGTX
RBC Inaugural Virtual Ophthalmology Conference26 Dec 2025 - All 11 children with LCA4 gained vision and developmental benefits after gene therapy.MGTX
Study Update23 Dec 2025